SCHEMBL4892673

SCHEMBL4892673

Nc1ccc(CCNC2C3CC4CC(C3)CC2C4)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.57
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 1/20 0.57
PKM P14618 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
EPHX2 P34913 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GFER P55789 1/20 0.42
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
PPID Q08752 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM3 P20309 1/20 0.39
HRH2 P25021 1/20 0.39
ADRA1A P35348 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6630960 0.77 NOS1 (0.51) LMNAKDM4EALDH1A1PKMTDP1
SCHEMBL4892582 0.76 PPID (0.42) LMNAKDM4EALDH1A1PKMTDP1
SCHEMBL30721688 0.75 KDM4E (0.59) LMNAKDM4EALDH1A1PKMTDP1
SCHEMBL3359246 0.73 EPHX2 (0.55) LMNAKDM4EALDH1A1PKMTDP1
SCHEMBL19524556 0.72 GRIN2B (0.54) LMNAKDM4EALDH1A1PKMTDP1
SCHEMBL1778693 0.71 SMN1; SMN2 (0.61) LMNAKDM4EALDH1A1PKMTDP1
SCHEMBL14411949 0.70 TAAR1 (0.57) LMNAKDM4EALDH1A1TDP1GFER
SCHEMBL15705344 0.69 CHRM2 (0.56) LMNAKDM4EALDH1A1PKMTDP1
SCHEMBL25343480 0.69 TAAR1 (0.59) KDM4ETDP1GFERMEN1KMT2A
SCHEMBL11149799 0.68 EPHX2 (0.60) LMNAKDM4EALDH1A1PKMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114007-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114007-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE FLT3, FES, ALK LMNA 3592/4885KDM4E 2073/4885ALDH1A1 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.